Wayne Poll, MD Chief Executive Officer






Wayne Poll completed his Urology training at the Massachusetts General Hospital where he was an Instructor in Surgery at The Harvard Medical School. In practice in Columbus, OH, his career focused on minimally invasive surgery, and specifcially laparoscopic and robotic techniques. He served as Chief of Surgery and Chief of Staff at OhioHealth, as well as the Director of Innovation. During 22 years of a mostly Oncology practice, he started and operated both a clinical trials management organization and a capitated payment management company. Dr, Poll has perosnally been the P.I. on multiple leading immuno-Oncology pivital trials. In 2009 Dr. Poll left practice to run the medical device company he founded, Minimally Invasive Devices, Inc. (MID) upon Series B financing. MID was a fully integrated medical device R&D, manufacturing, clinical trials, and sales and marketing company that developed the FloShield product line from ideation to global commercial sales. The product won multiple awards and was granted over 10 patents.


Edward W. Martin, JR, MD, FACS – Company Founder/ Chief Medical Officer/Board Member






Dr. Martin is a Professor of Surgery at The Ohio State University (OSU) and an Attending Surgical Oncologist at the Arthur G. James Cancer Hospital. Dr. Martin’s vision of intraoperative assessment of tumor biology and dissemination has spanned nearly 30 years of progress at OSU. Leading a team of innovators beginning in 1979, Dr. Martin developed the first hand-held probe capable of detecting cancer cells of colorectal, pancreatic, gastric, ovarian, prostatic, and breast origin in real-time in the operating room. The use of such hand-held probes has become the standard of care in the surgical management of many malignant and benign disease processes. Dr. Martin has significant patent and commercialization experience. His endeavors have generated six patents, and spawned four start-up companies which have developed an additional 78 U.S. patents.

Dr. Martin holds a degree in Medicine from Meharry Medical College (Nashville, TN) and completed his surgical training at OSU (Columbus, OH). His specialty training includes National Institutes of Health (NIH), OSU, and American Cancer Society Advanced Fellowship.

Art Morelli — Chief Business Officer








Mr. Morelli is a pharmaceutical industry professional with 30 + years of leadership experience at companies such as DuPont Merck Pharma, Elan Biopharmaceuticals, Cardinal Health, Solstice Neurosciences, Inc. and Covidien/Mallinckrodt Pharmaceuticals. At Du Pont Merck Mr. Morelli led the growth and expansion of the companies Emerging Markets pharmaceutical business in over 50 countries throughout Europe, Asia Pacific, Latin America and the Middle East regions. At Elan Biopharmaceuticals Mr. Morelli was VP of New Product Planning leading WW operations planning for the novel treatment for MS, Tysabri( natalizumab). Mr. Morelli was the co-founder and EVP of Commercial Operations for Solstice Neurosciences, Inc., a venture backed start-up which acquired the worldwide rights for Myobloc (botulinum toxin type B) from Elan. In this role, Mr. Morelli created and led the commercial infrastructure for the 150 person biopharmaceutical company located in South San Francisco, and led the expansion of the Myobloc brand into 28 countries. Recently, Art was the Vice President of Medical Affairs Operations at Covidien/Malinkrodt in St. Louis where he, reporting to the CMO, provided operations leadership to a 40 person Medical Affairs Dept. while overseeing a budget of nearly $ 30 million. In this position, Mr. Morelli successfully led the creation, planning, and launch of numerous key initiatives such as publications, investigator initiated clinical studies, REMS, and an innovative voluntary opioid safe use program, the CARES Alliance (

Art’s latest venture, Arthur F. Morelli and Associates, provides pharma companies with strategic and tactical solutions designed to optimize the effectiveness and efficiency of all aspects of their risk mitigation programs, and how to integrate risk mitigation with commercial activity.

Art, the recipient of numerous sales, marketing and overall performance awards, hold a bachelor’s degree in Biology from Wabash College where he was the captain of the cross-country team, and has completed a resident advanced educational program at Harvard Business School focused on global business. Art coaches an adult competitive running team comprised of athletes from across the country.


Herbert Neuman, MD, MBA – Regulatory Affairs Officer/Board Member

Herbert Neuman, MD, MBA 300dpi







Dr. Neuman serves as Enlyton’s Regulatory Affairs Officer and member of the Board of Directors. Dr. Neuman brings his strong background as a senior bio-pharmaceutical executive to our team. His experience in drug development and regulatory affairs will help drive the success of our ENL 210 clinical development program and subsequent approval by the FDA and other health authorities.

Board-certified in Internal Medicine, Dr. Neuman left clinical practice to join the pharmaceutical industry. During the course of his pharmaceutical career, he held a variety of senior executive positions, including Vice President of Global Regulatory Affairs, Vice President of Medical Affairs and Chief Medical Officer of a Fortune 500 global healthcare company. Throughout these roles, he successfully led efforts to gain initial marketing approval or expanded indications for multiple products around the world, including a wide-range of imaging diagnostics.
Dr. Neuman provides Enlyton with strategic guidance in the areas of new product regulatory pathways, product lifecycle management, business development & investment strategies, executive talent development, medical affairs, and drug safety. He is well-regarded as a leader in the area of advocacy before the US FDA, having extensive experience in articulating the risks and benefits of medicinal and diagnostic products to the FDA, including multiple face-to-face meetings at the FDA as well as at FDA public hearings and Advisory Committee meetings.


George H. Hinkle, MS, RPh – Chief Informations Officer






Mr. Hinkle is an Associate Professor of Pharmacy and Radiology at The Ohio State University (OSU). He has more than 25 years experience in radiopharmaceutical research/development primarily with radiolabeled antibodies and small molecules for tumor targeting. Mr. Hinkle has experience in leading clinical trials involving radiopharmaceuticals and will coordinate the laboratory development, pre-clinical chemistry and animal imaging of radiolabeled compounds using MicroPET/CT and tissue distribution/pharmacokinetic studies.

Mr. Hinkle holds a degree in Pharmacy and a masters degree in Nuclear Pharmacy, both from Purdue University (West Lafayette, IN)

Mr. Hinkle provides expertise in the clinical use of radiopharmaceutical agents, as Enlyton moves radiolabeled compounds into the clinical testing stages.

Thomas Magliery, PhD – Chief Science Officer

Dr. Magliery has substantial expertise in protein design, directed evolution and biophysical characterization, as well as enzymological characterization. As an independent investigator, Dr. Magliery has invented a  high-throughput screen for protein thermal stability, used bioinformatics to design stable proteins, and continued to improve chemical biology methods for studying weak protein interactions in cells. Dr. Magliery has studied the enzymology and engineered the physical properties of paraoxonase-1 for chemical warfare countermeasures. In 2012, Dr. Magliery began an effort to engineer stable, high-affinity antibody fragments for use in cancer imaging which has demonstrated that several of these are effective in xenograft mice.
  As a postdoctoral fellow with Lynne Regan, Dr. Magliery developed a cell-based screen for application of combinatorial methods to protein design, applied statistical analysis to the design of protein motifs, and made substantial improvements to a GFP-based method for trapping protein interactions in living cells. As a graduate student with Peter Schultz, Dr. Magliery engineered orthogonal enzyme-tRNA pairs by directed evolution, and engineered expanded-codon tRNAs, leading to the first living organisms capable of site-specific insertion of unnatural amino acids. In 8 years at OSU, Dr. Magliery has graduated 7 Ph.D. students, 2 M.S. students, and 10 senior honors students. His lab currently hosts 9 graduate students and 3 postdocs, as well as 6 undergraduate researchers and 2 research assistants/technicians.

 Edward W. Martin III, MBA – Chief Operations Officer


Mr. Martin has over 15 years experience in nuclear medicine research (BioCrystal Ltd, Westerville Ohio.), biotechnology business management (Interthyr Corporation, Athens, OH) and business consulting (Bose Corporation Framingham, MA and W.R. Grace Cambridge MA).

Mr. Martin holds a Masters degree in Business Administration from Northeastern University (Boston, MA).

As Enlyton COO, Martin oversees business operations, facilitates strategic technology development, and coordinates commercialization activities of the company.


Cathy M. Mojzisik, RN, MS — Vice President Clinical Development






 Ms. Mojzisik’s career in nursing includes over 30 years of clinical oncology research experience with over 50 peer reviewed journal articles and book chapters. As a clinical research coordinator at The Ohio State University, Ms. Mojzisik was instrumental in in the development and execution of Phase I-III clinical trials including investigations of tumor markers and radiolabeled monoclonal antibodies for intraoperative tumor detection and perioperative imaging and managed a multidisciplinary research team. She served as a member of the The James Clinical Scientific Review Committee. Her career in the pharmaceutical industry included the development of intraoperative education and training programs for Neoprobe sponsored clinical trials that were implement globally. Ms. Mojzisik has extensive experience in the contract research organization industry including monitoring clinical trials, managing clinical research associates, and serving as a senior project manager. Ms. Mojzisik holds a Bachelor of Science in Nursing degree from St. John College of Cleveland and a Master of Science in nursing degree from The Ohio State University.